Large pharmaceutical companies have promised to invest more than $370 billion over the next five years in the U.S., driven by Trump’s threat of pharma-specific tariffs.
The collaboration combines Chinese hamster ovary cell line development with GMP media manufacturing to improve productivity and scalability in biologics production.
The teaming focuses on improving lentiviral and AAV delivery technologies to support more scalable and cost-effective cell and gene therapy manufacturing.
